Kiniksa Pharmaceuticals Ltd.
(NASDAQ : KNSA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. 0.85%93.831.9%$1163.93m
BMYBristol-Myers Squibb Co. 0.71%61.321.0%$1017.19m
JNJJohnson & Johnson 0.37%147.270.7%$1009.80m
PFEPfizer Inc. -0.22%35.930.9%$970.99m
MRKMerck & Co., Inc. 0.82%82.220.7%$859.42m
LLYEli Lilly & Co. -1.02%149.171.1%$531.64m
AZNAstraZeneca Plc -0.04%53.851.2%$283.65m
NVSNovartis AG 0.93%85.910.2%$152.29m
GSKGlaxoSmithKline Plc 0.11%41.700.2%$126.54m
NVONovo Nordisk A/S 0.23%64.490.1%$83.99m
SNYSanofi 0.30%50.100.2%$78.95m
RGENRepligen Corp. -1.28%120.267.1%$68.99m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 1.08%68.140.0%$52.90m
RETAReata Pharmaceuticals, Inc. -2.49%126.303.4%$37.91m
TPTXTurning Point Therapeutics, Inc. 1.28%62.980.0%$37.82m

Company Profile

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.